Vantia Therapeutics Appoints Andrew Crockett as Vice President Business Development
Vantia Therapeutics announced the appointment of Andrew Crockett as Vice President business development.
Andrew joins Vantia from the US specialty pharma company ZARS Pharma where he was most recently Vice President Business Development. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences, and R&D alliances.
Andrew has studied at Harvard Business School and also holds an MBA from The Wharton School, University of Pennsylvania, with a major in Finance. He has served as an advisor to various investment groups for the medical device and pharmaceutical industries and is an advisory board member for US-based start ups.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.